RCS - e-Therapeutics plc - Investor Presentation

E-TherapeuticsAnnouncement

30/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230630:nRSd4376Ea&default-theme=true

RNS Number : 4376E  e-Therapeutics plc  30 June 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Investor Presentation

 

 

London, UK, 30 June 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, reminds interested investors that it will
hold an online live investor presentation titled "AI's Game-Changing Impact
on Drug Discovery" via Investor Meet Company on 3 July 2023 at 11:00am BST.

 

The presentation will be delivered by Ali Mortazavi, CEO of e-therapeutics
plc, and will run for approximately 40 minutes. After the presentation there
will be an opportunity for Q&A.

 

The presentation will be open to all existing and prospective shareholders.
New potential investors will need to sign up to Investor Meet Company for free
and add to meet e-therapeutics plc via:

https://www.investormeetcompany.com/e-therapeutics-plc/register-investor
(https://www.investormeetcompany.com/e-therapeutics-plc/register-investor)

 

Investors who already follow e-therapeutics plc on the Investor Meet Company
platform will automatically be invited.

 

Any questions can be submitted pre-event via your Investor Meet Company
dashboard up until 9:00am BST the day before the meeting or at any time during
the live presentation.

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                 Tel: +44 (0)20 4551 8888

 Laura Roca-Alonso, COO/CBO                                                         www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)

      SP Angel Corporate Finance LLP                                                Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary HepNet(TM) platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmic(TM), ETX's proprietary RNAi platform, enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNet(TM).  The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmic(TM)
constructs have demonstrated compelling in vivo performance in terms of
depth of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class preclinical RNAi
candidates across several high unmet medical needs in cardiometabolic
indications and targeting promising hepatocyte-expressed targets with effects
in other disease areas. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEALKNALSDEFA